Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ABY-039 in Healthy Volunteers
NCT03502954Phase 1Terminated
- Sponsor
- Affibody Medical AB
- Start
- Feb 2018
- Primary completion
- Feb 2020
- Modality
- Engineered Antibody Formats, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tifalibep in immunoglobulin G antibody-mediated disease (IgGMD) (4 arms), sponsored by Affibody Medical AB. Primary endpoint: Treatment Emergent Adverse Events at 11 weeks. Started Feb 2018; status: terminated.
02
Drugs
tifalibep
03
Conditions
immunoglobulin G antibody-mediated disease (IgGMD)
Beyond the preview
Go deeper on NCT03502954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502954.